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Abstract
Kidney stone disease is endemic. Extracorporeal shockwave lithotripsy was the first major 
technological breakthrough where focused shockwaves were used to fragment stones in the kidney 
or ureter. The shockwaves induced the formation of cavitation bubbles, whose collapse released 
energy at the stone, and the energy fragmented the kidney stones into pieces small enough to be 
passed spontaneously. Can the concept of microbubbles be used without the bulky machine? The 
logical progression was to manufacture these powerful microbubbles ex vivo and inject these 
bubbles directly into the collecting system. An external source can be used to induce cavitation 
once the microbubbles are at their target; the key is targeting these microbubbles to specifically 
bind to kidney stones. Two important observations have been established: (i) bisphosphonates 
attach to hydroxyapatite crystals with high affinity; and (ii) there is substantial hydroxyapatite in 
most kidney stones. The microbubbles can be equipped with bisphosphonate tags to specifically 
target kidney stones. These bubbles will preferentially bind to the stone and not surrounding 
tissue, reducing collateral damage. Ultrasound or another suitable form of energy is then applied 
causing the microbubbles to induce cavitation and fragment the stones. This can be used as an 
adjunct to ureteroscopy or percutaneous lithotripsy to aid in fragmentation. Randall’s plaques, 
which also contain hydroxyapatite crystals, can also be targeted to pre-emptively destroy these 
stone precursors. Additionally, targeted microbubbles can aid in kidney stone diagnostics by virtue 
of being used as an adjunct to traditional imaging methods, especially useful in high-risk patient 
populations. This novel application of targeted microbubble technology not only represents the 
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next frontier in minimally invasive stone surgery, but a platform technology for other areas of 
medicine.
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Introduction
Lifetime incidence of urinary stones is ≈10% for men and 7% for women, which 
corresponds to a prevalence of ≈2–3% in the general population. In all, 50% of patients with 
previous urinary stones will experience a recurrence within 5 years [1–3]. Major intra-
abdominal surgery was mainstay in the treatment of kidney and ureteric stones before the 
1980s, but was fraught with morbidity and mortality, even among experienced urologists 
[4,5]. However, over the last few decades there has been great expansion in minimally 
invasive techniques that has led to the dramatic decrease in open stone surgery [4,6]. ESWL 
was the first major breakthrough in stone surgery, which fragmented stones via acoustical 
pulses generated by a machine located outside a patient’s body [7]. This technology enabled 
urologists to treat patients with urinary stones without the morbidity and invasiveness of 
open surgery. As technology and optics improved, other minimally invasive methods for 
symptomatic urinary stone treatment have been developed including percutaneous 
nephrolithotomy (PCNL) and ureteroscopy (URS), but their comparative discussion is 
beyond the scope of this review.
ESWL
ESWL was initially developed in 1980 by Dornier Medizintechnik GmbH (now Dornier 
MedTech Systems, Germany) and has been widely used since the introduction of the first 
commercial lithotriptor Dornier Human Model 3 (HM3) in 1983 [8]. It has been used in the 
non-invasive treatment of many types of stones including kidney, bladder, salivary and 
biliary, using thousands of focused shockwaves generated outside the body to shatter stones 
into small fragments. Urinary stones pass spontaneously, but biliary stones typically require 
secondary procedures for removal. Lithotripters differ from one another in the method 
(electromagnetic, electrohydraulic, piezoceramic) used to generate shockwaves, but they all 
produce similar acoustic waves. Shockwaves are characterised by a rapid high energy peak, 
which differs from ultrasonic sinusoidal waves by its extremely large pressure amplitude. 
Additionally, ultrasound usually consists of a periodic oscillation, whereas a shockwave is a 
single pulse [8]. The focusing mechanism (fluoroscopy and/or ultrasonography) of the 
lithotriptor directs the shockwaves to a fixed second focal point (F2) target whereby the 
shockwaves becomes additive at the same location where the patient and their stone/s are 
positioned for treatment [9].
Mechanism of ESWL Stone Breakage
Cavitation is the primary mechanism by which shockwaves break stones into small pieces 
[8]. Shockwaves are focused onto a stone and the interaction between the shockwaves and 
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the stone created a negative pressure tail that induces the formation of strongly collapsing 
cavitation bubbles [10–13]. The bubble nucleus is initially compressed by the shockwaves 
and then rapidly expands and then collapses (cavitation), which liberates energy resulting in 
high-speed micro jets with strong erosion abilities to fragment nearby stones [14–16]. 
Cavitation plays a critical role in the generation of small stone fragments during lithotripsy. 
The lithotriptor machine is necessary to provide extracorporeal energy that generates 
shockwaves that are additive upon convergence at the F2 that create cavitation microbubbles 
[8]. Is it possible to deliver these microbubbles to offending urinary stones without the need 
for a large, expensive and bulky machine?
The Diminishing Role of ESWL
The original Dornier HM3 and other older general lithotripters had the most optimal 
coupling and resulted in the most efficient stone fragmentation [17]. Newer generation 
lithotripters have smaller F2 zones in hopes of reducing pain and potential renal injury; 
unfortunately, stone fragmentation rates have been significantly compromised [18,19]. 
Additional factors that influence the efficacy of ESWL include stone composition, skin to 
stone distance (body mass index), presence of anomalous renal anatomy, stone location, and 
associated hydronephrosis [4,8]. Typical side-effects include post-procedural gross 
haematuria, subcapsular haematoma (0.9%), occasional acute kidney injury, and rarely 
damage to surrounding organs [10,17,18,20,21]. Unconfirmed associations with 
hypertension and diabetes mellitus have been suggested [22,23].
Other minimally invasive techniques, such as PCNL and URS, have supplemented ESWL in 
treating kidney and ureteric stones with improved optics, smaller instruments and laser 
lithotripters that allow for direct visualisation of stone fragmentation [4]. Unlike ESWL, 
these other endoscopic approaches frequently require postoperative drainage with JJ ureteric 
stents and/or percutaneous nephrostomy tubes [4]. Could the principles of microbubble 
cavitation be leveraged during endoscopic approaches, including URS and PCNL, without 
the need for a large lithotriptor machine to optimise stone fragmentation? If this could be 
applied, it would provide a logical extension to making the treatment of stones more 
minimally invasive.
Microbubble Technology
Microbubbles have played a growing and significant role in medical therapeutics and 
diagnostics as contrast agents for ultrasonographic imaging [24–32]. The first use of this 
technology was in radiographic imaging to identify cardiac structural anomalies. Carbon 
dioxide (CO2) encapsulated microbubbles were first used as contrast agents in the venous 
circulation to delineate the right heart for evaluation of suspected ventricular septal defects. 
These microbubbles were comprised of perfluorocarbon gases, and injected into the 
systemic circulation. Subsequent echocardiography was performed to detect the presence of 
these microbubbles in the left ventricle, providing an ultrasonographic method for 
identifying the presence and magnitude of cardiac shunts [33]. Microbubbles have been used 
as an imaging agent for ultrasound in various other parts of the body with great success. 
Some have investigated its use in targeted destruction of tissue [34,35] or the restoration of 
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some vital tissue such as myocardium [36]. Recently, targeting ligands have been attached to 
the surface of the microbubbles, which have been widely used in the cardiovascular system, 
as well as for tumour diagnosis and therapy [37–39]. Others have combined microbubbles 
and ultrasound for drug delivery to brain tumours [40–42] and to other immunologically 
privileged areas. Other emerging applications of this technology include the effective 
opening of the blood–brain barrier, and for the therapeutic treatment of antimicrobial films 
[37].
Microbubble Synthesis and Preparation
Various microbubble products are available commercially; including microbubbles 
marketed under the trade names DEFINITY® (Lantheus Medical Imaging, Inc., N. Billerica, 
MA, USA) and OPTISON® (General Electric Imaging, Fairfield, CT, USA). The 
preparation of these Food and Drug Administration (FDA) approved commercially available 
non-targeted microbubbles is carried out according to already established and approved 
procedures, with appropriate modifications as necessary [39]. Tagged microbubbles are self-
assembled with a phospholipid surface and a perfluoronated carbon gas centre. These 
microbubbles have an average diameter between 0.1 and 10 μm. The contents of the 
microbubble can vary with application. For example, the bubble contains air, CO2, a 
fluorinated or perfluorinated gas, another gas, or mixtures of various gasses. Moreover, the 
microbubbles may initially be at a temperature such that a deflated microbubble may be 
injected into the patient, but will inflate as it heats to physiological temperatures (≈37 °C). 
These microbubbles can be filled partially or completely with a payload other than a gas, 
such as a pharmaceutically active agent, a cytotoxic agent, an imaging agent, or the like and 
delivered to a targeted organ or mass. To target urinary stones these stable, short-lived 
microbubbles (15–20 min) are synthesised with bisphosphonate surface tags to facilitate 
selective attachment to hydroxyapatite. After attaching the bisphosphonate chemical tags to 
the biocompatible microbubbles, the microbubbles are then delivered into a patient.
Our current approach is inspired by a microbubble solution developed by DEFINITY, which 
is comprised of a mixture of commercially available and FDA approved phospholipids. 
DEFINITY microbubbles encapsulate perfluoropropane, a gas which has been shown to be 
exhaled from the lungs with no toxic effects [43]. Specifically, our strategy involves 
chemical modification of the major phospholipid component present in the DEFINITY 
mixture, dipalmitoylphosphatidylcholine (DPPC) [44]. Initially, synthetic efforts are 
directed towards chemical modification of one of the methyl substituents on the amino 
group of DPPC, as the corresponding bisphosphonate derivatives can be readily accessed 
from commercially available starting materials using standard transformations (Fig. 1). 
Furthermore, chemical modification of the amino group in this fashion results in a minimal 
structural change to DPPC. It is reasonable to expect that these new bisphosphonate 
analogues will result in similar physical properties, such as solubility as well as improved 
stability in vivo when incorporated in microbubble solutions, and will retain the 
biocompatibility exhibited by DPPC.
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Microbubbles and Diagnostics
Targeted microbubbles can be used in the diagnosis of kidney stones. Targeted 
microbubbles as contrast materials require a small dosage and show excellent detection 
sensitivity [27–29]. CT is the ‘gold standard’ in radiographic diagnosis of kidney stones 
providing the highest sensitivity, but some stones (i.e. drug stones) are invisible even on CT 
[6]. Targeted microbubbles can bind to specific drug targets, revealing them on radiography. 
Plain X-ray is poor at visualising radiolucent stones (i.e. uric acid, cystine), but these stones 
can be specifically targeted to allow detection using simple plain radiographs. Stones in the 
parenchyma of the kidney can be differentiated from ones in the collecting system, thereby 
proving a more accurate measurement of stone burden. Traditionally MRI is poor at 
visualising stones [4], but microbubbles can be equipped with MRI-detectible ligands that 
have an affinity for kidney stones, thereby aiding in MRI detection. This may have a value 
in high-risk patient populations, such as pregnant women or children. Additionally, specifuc 
ligands (i.e. sulfhydryl groups) can be used to tag the microbubbles to detect specific stone 
types, providing a unique, non-invasive method in the diagnosis of kidney stones.
Targeted Microbubbles and Urological Applications
Lipid-coated microbubbles can be labelled to target specific tissue [27,36,45–47]. 
Microbubbles can be generated ex vivo with a functional group that is able to specifically 
target a particular substance or tissue. These microbubbles would subsequently bind 
selectively at the target site (i.e. kidney stone). The microbubbles would be induced to 
cavitate through the use of variety of energy sources. The rapid collapse of these 
microbubbles would release energy only at the site of interest. This minimally invasive 
technology has the potential to replicate the microbubbles generated in vivo from ESWL that 
can cavitate and fracture stones. The key is labelling the microbubbles to bind only onto the 
specific surface of the stones to minimise or eliminate complications and increase efficiency. 
How does one specifically target the urinary stones using microbubbles to direct their 
cavitation energy only to the stone? We explore observations that answer these questions.
Development of Kidney Stone Targeting
Based on X-ray diffraction, infrared spectroscopy, and chemical analysis hydroxyapatite is 
regarded as the principal inorganic constituent of bone mineral, built of crystals containing 
mainly calcium and phosphate [48–50]. Bisphosphonates are compounds that are used to 
treat or slow the progress of osteoporosis and bone-related events, by inhibiting osteoclastic 
bone resorption by attaching to hydroxyapatite binding sites on bony surfaces. They have a 
high affinity for calcium phosphate (hydroxyapatite or apatite) surfaces in the inorganic 
matrix of human bone where they preferentially attach [51–53]. Bone scanning is routinely 
performed with 99mTc-labelled diphosphonates that are similar to the bisphosphonates used 
for therapeutic applications. The principle uptake mechanism involves adsorption onto or 
into the crystalline structure of hydroxyapatite after i.v. administration [54]. Quantitative 
bone scintigraphy using a γ-camera allows for kinetic modelling to evaluate aspects of bone 
perfusion and metabolism, including conditions with diffuse alteration to bone remodelling 
(such as primary hyperparathyroidism, renal osteodystrophy, and osteoporosis), and for 
assessment of bone perfusion, regional metastasis, bone (graft) vitality and osteonecrosis 
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[55–57]. Can this same affinity of bisphosphonates to hydroxyapatite be exploited in urinary 
stone disease?
Most urinary stones are calcium based, and a significant portion is composed of 
hydroxyapatite. Many think that most biomineralisation starts with hydroxyapatite crystals. 
Additionally, these stones contain a number of cavities irregularly distributed throughout the 
entire interior that entomb small spheres of hydroxyapatite in the lattices of crystal sheets 
[58–61]. Theoretically with microbubbles tagged with bisphosphonates, the urinary stones 
can be specifically targeted; and can be used as an alternative minimally invasive treatment 
for stone fragmentation. A microbubble can have a specific targeting moiety (such as a 
bisphosphonate ligand) created ex vivo, that will have an affinity for hydroxyapatite in 
urinary stones after being injected into the urinary system.
Randall’s plaque is thought to be the initial nidus for many stones. Dr Alexander Randall 
[62] hypothesised that these papillary interstitial plaques were composed of calcium 
phosphate (hydroxyapatite), not calcium oxalate, and served as a nidus for subsequent stone 
formation. By injecting microbubbles that preferentially bind to the hydroxyapatite of these 
papillary plaques, one could theoretically cavitate and destroy them in hopes of reducing the 
nidi for future stone formation.
Other Urological Applications
An investigational technology called histotripsy is a novel technique that uses pulsed 
ultrasound that causes rapid cycles of compression and expansion, which in turn form 
microbubbles that have been used to fragment and homogenise unwanted tissue. It has been 
developed by a University of Michigan research team as a potential treatment for benign 
prostatic hyperplasia with good results in animal models. Human studies are pending [63–
65]. Histotripsy shows the versatility and power of microbubbles technology, but specific 
tissue targeting is performed by an external machine, but the individual microbubbles are 
not target specific.
Delivery of Microbubbles
This microbubble technology can be quickly prepared in the outpatient or the inpatient 
setting. These microbubbles can be injected into the urinary system and last about 15–20 
min before spontaneous dissolution. These targeted bisphosphonate laden microbubbles can 
concentrate and attach to the surfaces and inner crevices of urinary stones. Any excess 
bubbles not attached to the desired target can be washed away using a combination of a 
diuretic and/or fluid irrigation. This is important because excess bubbles can shield any 
applied energy source, interfering with the effect of the locally bound microbubbles. The 
passage of excess bubbles will allow for selectivity of the targeted stone and avoid collateral 
injury.
Targeting the Microbubbles
Prior medical applications of cavitation have used extracorporeal energy sources to create 
and collapse microbubbles in the tissue [32,63,66–68]. This new technology differs from 
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such procedures by using application-specific, gas-containing microbubbles that are 
manufactured ex vivo. The manufactured microbubbles contain targeting tags (e.g. 
bisphosphonates) that allow them to concentrate on or near the targeted tissue (e.g. urinary 
stones). They are then specifically delivered to the surface or vicinity of the desired target.
Energy Sources for Cavitation
Energy required to cause cavitation can be delivered in the form of electromagnetic radiation 
(e.g. radio or microwaves), or ultrasound waves. Due to its low electrical conductivity, 
electromagnetic frequencies between 400 and 10 000 kHz may be suitable because it 
propagates through tissue without strong interactions, while focusing on the intended target 
[69]. For example, standard ultrasound units are applied within or adjacent to the body with 
sufficient power to initiate cavitation of the pre-positioned bubbles.
Microbubbles for the Treatment of Kidney Stone Disease
Preferential Targeting of Kidney Stones
The bisphosphonate tags on the microbubbles, as previously described, have an affinity for 
the hydroxyapatite present in most urinary stones such that microbubbles bind to the target 
and not to surrounding fluid or tissue. Energy from a nearby source (ultrasound, radio 
frequency energy, or the like) is then applied to induce cavitation. The engineered 
microbubbles act as a cavitation nucleus upon interaction with the delivered energy and can 
fragment the targeted stone (Fig. 2 and accompanying Videos S1 and S2). Theoretically, 
when treating a patient with kidney or ureteric stones, the urologist can deliver these tagged 
microbubbles to a site within the patient (ureter or kidney) using routine endoscopes.
Delivery of Microbubbles to Kidney Stones
Delivery of the microbubbles into or near the targeted urinary stone can be achieved by 
various means. With ureteric stones, these microbubbles can be injected directly into the 
ureteric orifice using a flexible scope or even onto the stone using a small catheter placed up 
to the stone. If the stone is in the kidney, one can inject the microbubbles in a retrograde or 
an anterograde percutaneous fashion depending upon patient anatomy and location of stone 
fragments (Fig. 3). Randall’s plaques, which are precursors to calcium-based urinary stones, 
can also be targeted pre-emptively at the time of PCNL or URS. Many urologists have a 
sense of foreboding after endoscopic lithotripsy knowing these plaques will probably 
become recurrent stones – it is just a matter of time [62,70]. Microbubbles theoretically can 
be used to target these plaques at the time of URS or PCNL to pre-emptively destroy them; 
therefore, potentially reducing stone recurrence. Additionally, this technology can be used as 
an adjunct to URS or PCNL, where stones initially can be fragmented by traditional means, 
and microbubbles can subsequently be deployed to complete the conversion of these stone 
remnants into dust. This would be a manner in which to attempt to recreate the ‘popcorn 
effect’, where small fragments are obliterated into dust or gravel that would pass 
spontaneously.
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Energy Source for Cavitation of Kidney Stones
Energy needed to initiate cavitation can be delivered ex vivo as in traditional lithotripters. 
Alternatively a micro-energy source can be applied from the tip of a catheter or endoscope, 
which can be directed under fluoroscopic guidance or direct vision. This would enable the 
urologist to observe the resultant fragmentation in real-time. These catheters are readily 
available and widely used in other minimally invasive medical fields [71,72].
Platform Technology
Application of this targeted microbubble technology can be broadened outside of urological 
indications. Depending on specific needs, various formulations and preparations may be 
constructed to unique targets using surfactants or other additives for dispersal [73]. Delivery 
of specifically tagged microbubbles can be delivered through natural orifices such as the 
mouth, nose, eyes, vagina, urethra, and ears. It can also be delivered by s.c. injection and/or 
spray [74].
Conclusions
The novel application of targeted microbubble technology represents the next frontier in 
minimally invasive stone surgery, and our team envisions this as a platform technology in 
medicine. Traditional ESWL uses an extracorporeal energy source that creates microbubbles 
at the targeted stone, and subsequent cavitation leads to stone fragmentation. Targeted, 
tagged microbubbles eliminate the need for a large, bulky machine, and these unique 
microbubbles can be delivered directly to the offending stones. An energy source applied 
from either an extracorporeal or intracorporeal source can initiate the cavitation process, 
leading to stone fragmentation. This is the obvious extension of minimally invasive stone 
treatment. We envision the principles of this technology to be applied to other commonly 
appreciated pathological conditions in medicine.
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Abbreviations
DPPC dipalmitoylphosphatidylcholine
FDA USA Food and Drug Administration
HM3 Human Model 3
PCNL percutaneous nephrolithotomy
URS ureteroscopy
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Fig. 1. 
Structures of phospholipid-based microbubble forming compounds.
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Fig. 2. 
Ex vivo cavitation (top images) of stone. The same cavitation captured with rapid-shutter 
speed 1/1 000 000 second camera (below images). The microbubble coated calcium-based 
urinary stones show excellent fragmentation.
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Fig. 3. 
Synthesise microbubbles and inject into collecting system. External energy source used to 
cavitate attached microbubbles and break stones into small pieces.
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